<DOC>
	<DOCNO>NCT02176863</DOCNO>
	<brief_summary>This multicenter , prospective , randomize , placebo-controlled , double-blind , parallel group clinical trial adaptive dose selection subject post polio syndrome ( PPS ) . The main purpose study select dose Flebogamma 5 % DIF confirm efficacy select Flebogamma 5 % DIF dose assess physical performance , measure 2 Minutes Walk Distance ( 2MWD ) test .</brief_summary>
	<brief_title>Study Efficacy Safety Immune Globulin Intravenous ( Human ) Flebogamma® 5 % DIF Patients With Post-polio Syndrome</brief_title>
	<detailed_description>This phase II/III multicentre , prospective , randomize , placebo-controlled , double-blind , parallel‑group clinical trial adaptive design ( flexible group sequential design adaptive dose selection ) subject PPS . This study consist two stage . The first stage ( Stage 1 ) dose selection , second stage ( Stage 2 ) establish superiority ( efficacy confirmation ) Flebogamma® 5 % DIF overall safety analysis . At Stage 1 , three treatment arm , Flebogamma® 5 % DIF 2 g/kg body weight ( IVIG 2 g/kg arm ) , equivalent volume Normal Saline Solution ( 40 ml/kg body weight ) , Flebogamma® 5 % DIF 1 g/kg body weight plus equivalent volume Normal Saline Solution ( 20 ml/kg body weight ) ( IVIG 1 g/kg arm ) administer every 4 week two consecutive day 52-week treatment period . At Stage 2 , two treatment arm , select dose Flebogamma® 5 % DIF Stage 1 Normal Saline Solution ( 40 ml/kg body weight ) , administer every 4 week two consecutive day 52-week treatment period . During Stage 2 , select dose Flebogamma® 5 % DIF Normal Saline Solution administer manner Stage 1 , include administer total dose treatment arm volume equivalent IVIG 2 g/kg arm , regardless select dose . Primary efficacy endpoint : - Physical performance ( 2MWD ) baseline end treatment period ( End Treatment Visit -Week 52 ) . Secondary efficacy endpoint : - Pain ( VAS pain ) baseline end treatment period . - HRQoL ( SF-36 PCS ) baseline end treatment period . - Endurance ( 6MWD ) baseline end treatment period . Exploratory endpoint : - Muscle strength least two newly weaken muscle group ( Manual Muscle Testing [ MMT ] use modify Medical Research Council [ MRC ] scale ) baseline end treatment period . - Muscle strength least two newly weaken muscle group ( Quantitative Muscle Testing [ QMT ] use dynamometer ) baseline end treatment period . - Walking activity daily life ( pedometer ) baseline end treatment period . - Fatigue ( Fatigue Severity Scale [ FSS ] ) baseline end treatment period . - HRQoL ( SF-36 Mental Component Summary [ MCS ] ) baseline end treatment period . - Blood CSF ( CSF optional ) inflammatory cytokine ( IL-1 , IL-4 , IL-6 , IL-10 , IL-13 , IL-17 , IL-23 , TNF-alpha , IFN-gamma ) baseline end treatment period . - Sustained effect Flebogamma® 5 % DIF compare placebo measure : 1 . Physical performance ( 2MWD ) baseline Followup Visit ( FU ) ( Week 64 ) Final Visit ( FV ; Week 76 ) . 2 . Pain ( VAS pain ) baseline FU3 FV . 3 . HRQoL ( SF-36 PCS ) baseline FU3 FV . 4 . Endurance ( 6MWD ) baseline FU3 FV . 5 . Muscle strength ( MMT use MRC scale ) baseline FV . 6 . Muscle strength ( QMT use dynamometer ) baseline FV . 7 . Walking activity daily life ( pedometer ) baseline FV . 8 . Fatigue ( FSS ) baseline FV . 9 . HRQoL ( SF-36 MCS ) baseline FU3 FV . 10 . Blood CSF ( CSF optional ) inflammatory cytokine baseline FV . Safety endpoint include Adverse Events ( AEs ) , vital sign infusion , physical assessment blood test clinical safety .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Postpoliomyelitis Syndrome</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>BMI le 35 kg/m2 . MarchofDimes clinical criterion diagnosis PPS . Ambulatory able walk cane aid . Have least two newly weaken muscle group , one low extremity , define medical history mMRC scale score 3 great . Female childbearing potential must negative test pregnancy . Female childbearing potential sexual partner agree practice contraception use method proven reliability . Able walk 2MWD least 50 meter . Subjects able walk consistent baseline 2 MWD , , difference 2MWD SV EV/IV1 10 % . Have receive immune globulin treatment give intravenous , subcutaneous intramuscular route within last 3 year . Are ambulatory ( wheelchairbound individual ) . Poor venous access . Intractable pain require narcotic psychotropic drug . History anaphylactic reaction severe reaction bloodderived product . History intolerance component investigational product , sorbitol . Receiving corticosteroid , except asthma . Documented diagnosis hyperviscosity hypercoagulable state thrombotic complication polyclonal IVIG therapy past . History recent ( within last year ) myocardial infarction , stroke , uncontrolled hypertension . Suffer congestive heart failure , embolism , electrocardiogram change indicative unstable angina atrial fibrillation . History chronic alcoholism illicit drug abuse ( addiction ) precede 12 month . Active psychiatric illness interferes compliance communication health care personnel . Depression score &gt; 30 assess Center Epidemiologic Studies Depression validate scale . Females pregnant nursing infant child . Currently receive , receive within 3 month prior Screening Visit , investigational medicinal product device . Known selective IgA deficiency serum antibody antiIgA . Renal impairment ( i.e. , serum creatinine exceed 1.5 time upper limit normal ( ULN ) . Subjects aspartate aminotransferase alanine aminotransferase level exceed 2.5 time ULN . Hemoglobin level &lt; 10 mg/dL , platelet level &lt; 100,000/mm3 , white blood cell count &lt; 3.0 k/µL ESR &gt; 50 mm/h twice normal . Known seropositive Hepatitis C virus , Human immunodeficiency virus1 and/or 2 . Subjects history intolerance fructose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>FORCE</keyword>
	<keyword>post-polio syndrome</keyword>
	<keyword>Flebogamma</keyword>
	<keyword>Immune Globulin Intravenous</keyword>
	<keyword>IGIV</keyword>
</DOC>